Viterbo D, Gausman V, Gonda T. Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy. World J Gastrointest Endosc 2016; 8(3): 128-142 [PMID: 26862363 DOI: 10.4253/wjge.v8.i3.128]
Corresponding Author of This Article
Tamas Gonda, MD, Assistant Professor of Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, 161 Fort Washington Avenue, Suite 862, New York, NY 10032, United States. tg2214@cumc.columbia.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Endosc. Feb 10, 2016; 8(3): 128-142 Published online Feb 10, 2016. doi: 10.4253/wjge.v8.i3.128
Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy
Domenico Viterbo, Valerie Gausman, Tamas Gonda
Domenico Viterbo, Tamas Gonda, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY 10032, United States
Valerie Gausman, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, United States
Author contributions: Viterbo D, Gausman V and Gonda T contributed to the literature search, drafting of the manuscript, proof-reading and approval of the final version for submission; Viterbo D and Gausman V contributed equally to this work.
Conflict-of-interest statement: All authors declare that we have no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Tamas Gonda, MD, Assistant Professor of Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, 161 Fort Washington Avenue, Suite 862, New York, NY 10032, United States. tg2214@cumc.columbia.edu
Telephone: +1-212-3051909 Fax: +1-212-3051081
Received: July 29, 2015 Peer-review started: July 29, 2015 First decision: October 13, 2015 Revised: October 17, 2015 Accepted: December 7, 2015 Article in press: December 8, 2015 Published online: February 10, 2016 Processing time: 186 Days and 6.4 Hours
Abstract
Pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) are two malignancies that carry significant morbidity and mortality. The poor prognoses of these cancers are strongly related to lack of effective screening modalities as well as few therapeutic options. In this review, we highlight novel biomarkers that have the potential to be used as diagnostic, prognostic and predictive markers. The focus of this review is biomarkers that can be evaluated on endoscopically-obtained biopsies or brush specimens in the pre-operative setting. We also provide an overview of novel serum based markers in the early diagnosis of both PDAC and CCA. In pancreatic cancer, the emphasis is placed on prognostic and theranostic markers, whereas in CCA the utility of molecular markers in diagnosis and prognosis are highlighted.
Core tip: The poor prognoses of pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) are strongly related to lack of effective screening modalities as well as few therapeutic options. Several novel biomarkers have been studied that have shown promise for early diagnosis and targeted therapy of these malignancies. These biomarkers provide a strong background for future clinical studies to screen for PDAC and CCA in the general population as well as to investigate molecularly targeted therapies.
